SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a major focus of community debate, with investors split between those anticipating a major breakout driven by ecosystem developments and others dismissing the asset as a speculative project. Many participants are actively monitoring potential burn mechanisms and network updates while debating the long-term viability of the token compared to other meme coins.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently trending due to intense community debate surrounding its sharp decline toward multi-year lows and concerns over potential capitulation. Investors are actively discussing whether the current price levels represent a high-upside accumulation opportunity or a value trap, with many drawing comparisons to other volatile sectors and speculating on the impact of future regulatory clarity.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending as investors weigh strong oncology pipeline readouts and new FDA priority reviews for hypertension treatments against the broader impact of looming U.S. tariff negotiations and manufacturing investment commitments. The community is actively debating the company's long-term revenue growth targets and how strategic collaborations will help maintain competitive positioning as key patents approach expiration.

ProShares Trust II - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver is attracting intense community attention as traders debate whether the recent volatility represents a buying opportunity or a deeper correction linked to U.S. interest rate sensitivity and industrial demand. Investors are actively discussing the risks of leveraged decay versus the potential for a rebound, while closely monitoring the metal's performance against dollar strength and macroeconomic catalysts.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending as investors digest the recent licensing deal for siRNA programs and pivot toward the company's long-term growth strategy rather than an immediate buyout. The community remains focused on robust commercial momentum for Rezdiffra and the upcoming earnings report, with several analysts raising price targets despite recent volatility.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is currently a focal point for investors as the community debates whether the stock is significantly undervalued following a pullback, with many pointing to its profitable commercial portfolio and a high level of short interest as catalysts for a potential squeeze. Bullish sentiment remains anchored in the upcoming VEPPANU launch and institutional confidence, while skeptics are voicing frustration over leadership's long-term stock performance and recent volatility.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's XRP is trending as optimism builds around the potential passage of the Clarity Act, which investors believe could provide the regulatory certainty needed for institutional adoption. The community is actively debating the project's long-term utility as a global settlement asset versus its recent flat price performance, with many watching for potential legislative developments to break the current trading range.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is currently in the spotlight as a key partner in the DOE-backed Project Prometheus, an initiative leveraging AI-driven research from NVIDIA and AWS to accelerate the deployment of advanced nuclear reactors. The community is actively discussing its potential to address surging power demands from AI data centers, though investors remain cautious, weighing the company's significant growth pipeline against execution risks and its current pre-profit status.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened scrutiny as market participants remain deeply divided between those holding long-term conviction in its meme-driven potential and those dismissing it as a stagnant asset. Community discussion is currently dominated by debates over its long-term viability, speculation surrounding institutional involvement, and cautious monitoring of key support levels amidst broader cryptocurrency market volatility.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF (MAGS) is trending as investors aggressively rotate capital between these mega-cap leaders and semiconductor stocks, while actively debating whether high AI infrastructure spending acts as a sustainable growth engine or a balance sheet burden. The community remains focused on upcoming earnings and Fed policy shifts, with many traders monitoring critical support levels for signs of trend exhaustion or potential rotation back into tech growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress

Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress...

Why Is Legend Biotech Stock Falling Thursday?

Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.read more...

Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in pre-market trading.read more...

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets.read...

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech Q1 Earnings Call Highlights...

Legend Biotech (LEGN) Projected to Post Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Zurcher Kantonalbank Zurich Cantonalbank Decreases Stake in Legend Biotech Corporation Sponsored ADR $LEGN

Zurcher Kantonalbank Zurich Cantonalbank lowered its stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 89.4% in the fourth quarter, according to the company in its most...

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen research firms that are currently covering the...

Legend Biotech Corporation Sponsored ADR $LEGN Stock Holdings Lowered by Matthews International Capital Management LLC

Matthews International Capital Management LLC reduced its holdings in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 7.0% during the 4th quarter, according to its most recent...

Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?

Legend Biotech (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

LEGN Stock Clocks Best Day In Three Years — What’s Driving The Rally?

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$22.22
Prev Close	$23.53
Open	$22.80
Dividend Yield	0.00%
50-Day Moving Average	$28.83
Beta	0.53
Avg. Volume	3.47M
PE Ratio	-16.34

52-Week High	$43.71
52-Week Low	$16.24
Market Capitalization	$4.13B
EPS (Annual)	-$1.61
Price to Book	4.26
Revenue Per Employee	$355,731.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

LEGNLegend Biotech

Latest LEGN News